Frankfurt - Delayed Quote EUR
Nanexa AB (publ) (40M.F)
0.1798
+0.0158
+(9.63%)
At close: June 13 at 8:07:01 AM GMT+2
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Westberg | Chief Executive Officer | 3.15M | -- | 1960 |
| Mr. Marten Rooth | Co-Founder & CTO | -- | -- | 1977 |
| Mr. Anders Johansson | Co-Founder & Head of Intellectual Property | 996k | -- | 1976 |
| Ms. Cecilia Danckwardt-Lilliestrom | Chief Financial Officer | -- | -- | 1961 |
| Mr. Mikael Asp | Head of QA & Special Advisor | -- | -- | 1962 |
| Mr. Joel Hellrup | Head of Pharmaceutical R&D | -- | -- | 1983 |
| Polla Rouf | Head of ALD R&D | -- | -- | -- |
| Ms. Bridget Lacey B.Sc. | Chief Business Officer | -- | -- | -- |
| Mr. Otto Skolling M.Sc | Director of Business Development | 867k | -- | 1961 |
Nanexa AB (publ)
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 13
Description
Nanexa AB (publ) operates as a nanotechnology drug delivery company. The company operates PharmaShell, a drug delivery system that is an atomic layer deposition. It also develops NEX-22 for the treatment of type 2 diabetes. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Corporate Governance
Nanexa AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 27, 2025 at 10:59 AM UTC
Nanexa AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available